These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. ROS1--targeting the one percent in lung cancer. Gold KA N Engl J Med; 2014 Nov; 371(21):2030-1. PubMed ID: 25409376 [No Abstract] [Full Text] [Related]
4. Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients. Juan O; Popat S Lung Cancer; 2017 Feb; 104():131-133. PubMed ID: 27863911 [No Abstract] [Full Text] [Related]
5. Crizotinib in ROS1-rearranged non-small-cell lung cancer. Shaw AT; Ou SH; Bang YJ; Camidge DR; Solomon BJ; Salgia R; Riely GJ; Varella-Garcia M; Shapiro GI; Costa DB; Doebele RC; Le LP; Zheng Z; Tan W; Stephenson P; Shreeve SM; Tye LM; Christensen JG; Wilner KD; Clark JW; Iafrate AJ N Engl J Med; 2014 Nov; 371(21):1963-71. PubMed ID: 25264305 [TBL] [Abstract][Full Text] [Related]
6. Crizotinib in ROS1 rearranged non-small cell lung cancer (NSCLC), from response to resistance. Zhong E; Huang H BMJ Case Rep; 2016 Oct; 2016():. PubMed ID: 27797842 [TBL] [Abstract][Full Text] [Related]
7. [Crizotinib for ROS1-rearranged non-small cell lung cancer patients]. Domblides C; Antoine M; Lavole A; Cadranel J; Wislez M Bull Cancer; 2017 Apr; 104(4):303-310. PubMed ID: 28237354 [TBL] [Abstract][Full Text] [Related]
8. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers. Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242 [TBL] [Abstract][Full Text] [Related]
9. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient. Lu S; Azada MC; Ou SH Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789 [TBL] [Abstract][Full Text] [Related]
10. Lung cancer: alternative rearrangements--targeting ROS1 in NSCLC. Killock D Nat Rev Clin Oncol; 2014 Nov; 11(11):624. PubMed ID: 25311353 [No Abstract] [Full Text] [Related]
11. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554 [TBL] [Abstract][Full Text] [Related]
13. Response to crizotinib observed in metastatic mediastinum lymph node from a non-small cell lung cancer patient harboring EZR-ROS1 fusion. Li H; Pan Y; Wang R; Li Y; Sun Y; Chen H J Cancer Res Clin Oncol; 2015 Jan; 141(1):185-7. PubMed ID: 25230898 [No Abstract] [Full Text] [Related]
14. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280 [TBL] [Abstract][Full Text] [Related]
15. ROS1 rearranged nonsmall cell lung cancer and crizotinib: An Indian experience. Noronha V; Chandrakanth MV; Joshi AP; Patil V; Chougule A; Mahajan A; Janu AK; Chanana R; Prabhash K Indian J Cancer; 2017; 54(2):436-438. PubMed ID: 29469073 [TBL] [Abstract][Full Text] [Related]
16. Crizotinib in the management of advanced-stage non-small-cell lung cancer. Loong HH; Mok K; Leung LK; Mok TS Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678 [TBL] [Abstract][Full Text] [Related]
17. ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives. Guisier F; Piton N; Salaun M; Thiberville L Clin Lung Cancer; 2019 Nov; 20(6):e593-e596. PubMed ID: 31395437 [No Abstract] [Full Text] [Related]
18. Crizotinib in the treatment of non--small-cell lung cancer. Rothschild SI; Gautschi O Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969 [TBL] [Abstract][Full Text] [Related]
19. Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer. Solomon B J Clin Oncol; 2015 Mar; 33(9):972-4. PubMed ID: 25667277 [No Abstract] [Full Text] [Related]
20. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Bos M; Gardizi M; Schildhaus HU; Heukamp LC; Geist T; Kaminsky B; Zander T; Nogova L; Scheffler M; Dietlein M; Kobe C; Holstein A; Maintz D; Büttner R; Wolf J Lung Cancer; 2013 Jul; 81(1):142-3. PubMed ID: 23558310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]